High levels of Bcl-2 promote cell survival and tumorigenesis and have been associated with poor outcomes and resistance to traditional anti-myeloma agents; therefore, Bcl-2 represents an attractive target for novel therapies. This evidence concerns the gene BCL2 and plasma cell myeloma.